4CF Group started in 2007 as a specialty manufacturer of oral dissolved films. Customers kept asking us to handle the regulation and source the ingredients too. Today we run three businesses for the same reason — they compound when bought from one partner.
Contract manufacturing of oral dissolved films, strips, patches and adjacent thin-form formats. Two captive lines and a vetted partner network across Asia and Europe.
See manufacturingAn end-to-end GMP and regulatory partner across pharma, medical device, food and cosmetic — connected to GlobalRegAI for live intelligence across 22 authorities.
See consultingA direct-sales ingredient house with 1,400+ items across nutrition, cosmetic, pharma and industrial — backed by a co-development R&D team that publishes its work.
See ingredientsSuwon facility opens with a single ODF casting line. Early customers are local pharma and OTC brands looking for an alternative to tablet formats.
What started as in-house dossier work for our own customers became a standalone consulting practice — handling pharma cGMP, ISO and the first wave of medical device submissions for external clients.
Direct-import of speciality polymers, excipients and botanical actives for film customers. The catalogue grows quickly as cosmetic and food customers ask us to source for them too.
Basel and Osaka contract partners formalised. Three sectors now operate across APAC and EU under one quality manual; zero critical findings in routine inspections from this year forward.
27 peer-reviewed papers later, co-development with academic and customer partners becomes a formal offering across all three sectors.
Live regulatory intelligence across 22 authorities is now embedded into the consulting practice and exposed to customers as a self-serve search interface — the next step in compounding the three sectors.
Customers shouldn't have to integrate three vendors. We carry the molecule from feasibility through manufacture, regulation, and supply — and one account team owns the timeline.
The first conversation is with our R&D and regulatory leads, not a salesperson. We say no early when something cannot be done safely — and tell you what would have to be true to change that.
We chose capital-light, modular manufacturing on purpose. It lets us run 50,000-unit pilots and 100M-unit campaigns on the same line — without forcing customers to commit to volumes they don't have yet.
Every ingredient supplier audited on-site every 24 months. Every lot ships with CoA, CoO and a customs-cleared paper trail. Every QMS surveilled annually. Boring but essential.
Our R&D team has 27 peer-reviewed papers across film stability, ingredient delivery and cosmetic actives. When the science is original, we'd rather share it than hide it behind a sales deck.
NDA is offered before any technical conversation. Customer data, formulations and pipeline information are siloed across sectors — even internally, on a need-to-know basis.